UBS Group’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-8,400
Closed -$148K – 9460
2021
Q2
$148K Hold
8,400
– – ﹤0.01% 5578
2021
Q1
$212K Buy
+8,400
New +$164K ﹤0.01% 5441
2019
Q3
– Sell
-103,000
Closed -$226K – 7947
2019
Q2
$226K Buy
+103,000
New +$561K ﹤0.01% 4847

Other funds holding ACRS

UBS Group's ACRS Position: Q3 2026 in Review

UBS Group increased its Aclaris Therapeutics (ACRS) stake by 89% in Q3 2026, buying an estimated $1.3M and bringing the position to 484,501 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4800.

UBS Group first reported a position in ACRS in Q4 2015 and has held it in 44 quarters since. The position peaked at $9.7M in Q4 2018. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • UBS Group held 484,501 shares of Aclaris Therapeutics worth $2.55M as of Q3 2026.
  • UBS Group bought 227,500 Aclaris Therapeutics shares in Q3 2026, an estimated $1.3M.
  • Aclaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4800 holding.
  • UBS Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 44 quarters since.
  • UBS Group's Aclaris Therapeutics position peaked at $9.7M in Q4 2018.
  • 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.